NSG 5240 Advanced Pharmacology midterm Exam | Complete
Practice QUESTIONs, Verified Answers & Detailed Rationales
(2026/2027)
QUESTION 1
A clinical pharmacologist evaluates a drug with a very high volume of
distribution (𝑉𝑑 ). What does this pharmacokinetic parameter imply
regarding the drug's distribution characteristics in the body?
• A. The drug is confined primarily to the vascular compartment and
binds extensively to plasma proteins.
• B. The drug extensively leaves the vascular compartment and
distributes widely into extravascular tissues, such as fat and
muscle.
• C. The drug is rapidly excreted unchanged by the renal glomeruli.
• D. The drug has an extremely short biological half-life.
Correct Answer: B. The drug extensively leaves the vascular
compartment and distributes widely into extravascular tissues, such as
fat and muscle.
Detailed Rationale: Volume of distribution (𝑉𝑑 ) is a proportionality
constant relating the total amount of drug in the body to its plasma
concentration. A high 𝑉𝑑 indicates that the drug readily crosses capillary
membranes and sequesters into peripheral tissues (e.g., adipose tissue
or skeletal muscle) rather than remaining confined to the plasma.
QUESTION 2
,How does a partial agonist differ from a full agonist at a receptor site?
• A. A partial agonist binds to a different allosteric site and blocks all
receptor activity.
• B. A partial agonist produces a submaximal efficacy (lower intrinsic
activity) even when all receptors are occupied, and can act as an
antagonist in the presence of a full agonist.
• C. A partial agonist binds irreversibly, permanently inactivating the
receptor.
• D. A partial agonist has a higher affinity for the receptor than any
full agonist.
Correct Answer: B. A partial agonist produces a submaximal efficacy
(lower intrinsic activity) even when all receptors are occupied, and can
act as an antagonist in the presence of a full agonist.
Detailed Rationale: Partial agonists possess intrinsic activity greater
than zero but less than one. Consequently, they cannot produce the
maximal physiological response of a full agonist. When given alongside
a full agonist, a partial agonist occupies receptors and competitively
blocks the full agonist, effectively lowering the maximal response.
QUESTION 3
A medication is administered by continuous intravenous infusion. It
exhibits zero-order elimination kinetics at therapeutic doses. What is
the fundamental characteristic of zero-order elimination?
• A. A constant fraction of the drug is eliminated per unit of time,
regardless of plasma concentration.
, • B. A constant amount of drug is eliminated per unit of time,
because elimination mechanisms are saturated.
• C. The elimination half-life remains entirely constant at all plasma
concentrations.
• D. The rate of elimination is directly proportional to the plasma
drug concentration.
Correct Answer: B. A constant amount of drug is eliminated per unit of
time, because elimination mechanisms are saturated.
Detailed Rationale: Unlike first-order elimination (where a constant
fraction is cleared per unit time), zero-order kinetics occur when drug-
metabolizing enzymes or transport systems become saturated. As a
result, a fixed amount of drug is cleared per unit of time, leading to
non-linear pharmacokinetics and potential toxicity with small dose
increases.
QUESTION 4
During a pharmacology lecture, the professor discusses autonomic
neurotransmission. Which receptor subtype mediates smooth muscle
contraction and glandular secretion via the Gq protein-coupled
phospholipase C pathway at parasympathetic target organs?
• A. Nicotinic (𝑁𝑚 ) receptors
• B. Muscarinic (𝑀2 ) receptors
• C. Muscarinic (𝑀1 and 𝑀3 ) receptors
• D. Beta-1 adrenergic receptors
Correct Answer: C. Muscarinic (𝑀1 and 𝑀3 ) receptors
, Detailed Rationale: 𝑀1 and 𝑀3 muscarinic receptors couple to Gq
proteins, activating phospholipase C, which leads to IP3 and DAG
production, intracellular calcium release, and subsequent smooth
muscle contraction and glandular secretion. (𝑀2 couples to Gi, slowing
heart rate).
QUESTION 5
A patient presents to the emergency department following accidental
ingestion of an unknown plant containing belladonna alkaloids,
exhibiting severe antimuscarinic toxicity ("blind as a bat, mad as a
hatter, red as a beet, dry as a bone, hot as a hare"). Which medication is
the specific antidote used to reverse central and peripheral
anticholinergic toxicity?
• A. Atropine
• B. Physostigmine
• C. Neostigmine
• D. Succinylcholine
Correct Answer: B. Physostigmine
Detailed Rationale: Physostigmine is a tertiary amine anticholinesterase
inhibitor that readily crosses the blood-brain barrier. By increasing
acetylcholine concentrations in both the central and peripheral nervous
systems, it effectively reverses severe antimuscarinic poisoning.
QUESTION 6
A patient is given an injection of epinephrine. When administered at
high clinical doses, which adrenergic receptor subtype predominates in
Practice QUESTIONs, Verified Answers & Detailed Rationales
(2026/2027)
QUESTION 1
A clinical pharmacologist evaluates a drug with a very high volume of
distribution (𝑉𝑑 ). What does this pharmacokinetic parameter imply
regarding the drug's distribution characteristics in the body?
• A. The drug is confined primarily to the vascular compartment and
binds extensively to plasma proteins.
• B. The drug extensively leaves the vascular compartment and
distributes widely into extravascular tissues, such as fat and
muscle.
• C. The drug is rapidly excreted unchanged by the renal glomeruli.
• D. The drug has an extremely short biological half-life.
Correct Answer: B. The drug extensively leaves the vascular
compartment and distributes widely into extravascular tissues, such as
fat and muscle.
Detailed Rationale: Volume of distribution (𝑉𝑑 ) is a proportionality
constant relating the total amount of drug in the body to its plasma
concentration. A high 𝑉𝑑 indicates that the drug readily crosses capillary
membranes and sequesters into peripheral tissues (e.g., adipose tissue
or skeletal muscle) rather than remaining confined to the plasma.
QUESTION 2
,How does a partial agonist differ from a full agonist at a receptor site?
• A. A partial agonist binds to a different allosteric site and blocks all
receptor activity.
• B. A partial agonist produces a submaximal efficacy (lower intrinsic
activity) even when all receptors are occupied, and can act as an
antagonist in the presence of a full agonist.
• C. A partial agonist binds irreversibly, permanently inactivating the
receptor.
• D. A partial agonist has a higher affinity for the receptor than any
full agonist.
Correct Answer: B. A partial agonist produces a submaximal efficacy
(lower intrinsic activity) even when all receptors are occupied, and can
act as an antagonist in the presence of a full agonist.
Detailed Rationale: Partial agonists possess intrinsic activity greater
than zero but less than one. Consequently, they cannot produce the
maximal physiological response of a full agonist. When given alongside
a full agonist, a partial agonist occupies receptors and competitively
blocks the full agonist, effectively lowering the maximal response.
QUESTION 3
A medication is administered by continuous intravenous infusion. It
exhibits zero-order elimination kinetics at therapeutic doses. What is
the fundamental characteristic of zero-order elimination?
• A. A constant fraction of the drug is eliminated per unit of time,
regardless of plasma concentration.
, • B. A constant amount of drug is eliminated per unit of time,
because elimination mechanisms are saturated.
• C. The elimination half-life remains entirely constant at all plasma
concentrations.
• D. The rate of elimination is directly proportional to the plasma
drug concentration.
Correct Answer: B. A constant amount of drug is eliminated per unit of
time, because elimination mechanisms are saturated.
Detailed Rationale: Unlike first-order elimination (where a constant
fraction is cleared per unit time), zero-order kinetics occur when drug-
metabolizing enzymes or transport systems become saturated. As a
result, a fixed amount of drug is cleared per unit of time, leading to
non-linear pharmacokinetics and potential toxicity with small dose
increases.
QUESTION 4
During a pharmacology lecture, the professor discusses autonomic
neurotransmission. Which receptor subtype mediates smooth muscle
contraction and glandular secretion via the Gq protein-coupled
phospholipase C pathway at parasympathetic target organs?
• A. Nicotinic (𝑁𝑚 ) receptors
• B. Muscarinic (𝑀2 ) receptors
• C. Muscarinic (𝑀1 and 𝑀3 ) receptors
• D. Beta-1 adrenergic receptors
Correct Answer: C. Muscarinic (𝑀1 and 𝑀3 ) receptors
, Detailed Rationale: 𝑀1 and 𝑀3 muscarinic receptors couple to Gq
proteins, activating phospholipase C, which leads to IP3 and DAG
production, intracellular calcium release, and subsequent smooth
muscle contraction and glandular secretion. (𝑀2 couples to Gi, slowing
heart rate).
QUESTION 5
A patient presents to the emergency department following accidental
ingestion of an unknown plant containing belladonna alkaloids,
exhibiting severe antimuscarinic toxicity ("blind as a bat, mad as a
hatter, red as a beet, dry as a bone, hot as a hare"). Which medication is
the specific antidote used to reverse central and peripheral
anticholinergic toxicity?
• A. Atropine
• B. Physostigmine
• C. Neostigmine
• D. Succinylcholine
Correct Answer: B. Physostigmine
Detailed Rationale: Physostigmine is a tertiary amine anticholinesterase
inhibitor that readily crosses the blood-brain barrier. By increasing
acetylcholine concentrations in both the central and peripheral nervous
systems, it effectively reverses severe antimuscarinic poisoning.
QUESTION 6
A patient is given an injection of epinephrine. When administered at
high clinical doses, which adrenergic receptor subtype predominates in
